Royalty Pharma Declares Second Quarter 2026 Dividend

Rhea-AI Summary

Royalty Pharma (Nasdaq: RPRX) announced a $0.235 dividend per Class A ordinary share for Q2 2026. The dividend is payable on June 10, 2026 to shareholders of record at the close of business on May 15, 2026.

Positive

• $0.235 per share dividend declared for Q2 2026
• Clear payment schedule: record date May 15, 2026 and pay date June 10, 2026

Negative

• Dividend creates a cash outflow on June 10, 2026 that reduces company cash resources

News Market Reaction – RPRX

+3.14%

1 alert

+3.14% News Effect

On the day this news was published, RPRX gained 3.14%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ordinary share.

The dividend will be paid on June 10, 2026, to shareholders of record at the close of business on May 15, 2026.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT, and Gilead’s Trodelvy, and 19 development-stage product candidates. For more information, visit www.royaltypharma.com.   

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6637
ir@royaltypharma.com

FAQ

How much is Royalty Pharma (RPRX) paying per share for the Q2 2026 dividend?

Royalty Pharma is paying $0.235 per Class A share for the second quarter of 2026. According to Royalty Pharma, the dividend amount applies to Class A ordinary shares and will be paid on June 10, 2026 to shareholders of record May 15, 2026.

When is the RPRX Q2 2026 dividend record date and payment date?

The record date is May 15, 2026 and the payment date is June 10, 2026. According to Royalty Pharma, shareholders of record at the close of business on May 15 will receive the dividend on the June 10 payment date.

Which shares are eligible for Royalty Pharma's $0.235 dividend for Q2 2026?

The dividend applies to Class A ordinary shares for Q2 2026. According to Royalty Pharma, only holders of Class A ordinary shares on the May 15, 2026 record date are eligible for the June 10, 2026 payment.

How will the RPRX dividend payment affect shareholders who buy shares before the record date?

Buyers who hold Class A shares by market close on May 15, 2026 should be on record to receive the dividend. According to Royalty Pharma, eligibility is determined by shareholder record at the close of business on the stated record date.

Does Royalty Pharma's Q2 2026 dividend announcement change its regular dividend policy?

The announcement declares a $0.235 dividend for Q2 2026 but does not state a policy change. According to Royalty Pharma, the release specifies the dividend amount, record date May 15, 2026, and payment date June 10, 2026 without additional policy commentary.